Loading
Loading…
Loading…
| # | Company | Amount | Rank | Status |
|---|---|---|---|---|
| 1 | L1₹6.5 LAdmitted-Finance | ₹6.5 L | L1 | Admitted-Finance |
| 2 | L2₹6.9 L+₹41,744.89 (6.43%)Admitted-Finance | ₹6.9 L+₹41,744.89 (6.43%) | L2 | Admitted-Finance |
| Sl No | Description | Qty | Unit | Ikris Pharma Network Pvt. Ltd. L1 | ALLEVIARE LIFE SCIENCES PVT LTD L2 |
|---|---|---|---|---|---|
| 1.00RARE DISEASE MEDICINE | |||||
| 1.01 | Inj. Glofitamab 2.5mg | 1 | per vial | 1,72,003.48 ₹1,72,003.48 | 1,58,604.71 ₹1,58,604.71 Lowest |
| 2.01 | Inj. Glofitamab 10mg | 1 | per vial | 4,77,608.34 ₹4,77,608.34 Lowest | 5,32,752 ₹5,32,752 |
Tender Value
Refer Docs
EMD Value
₹50,000
Closing Date
6 Apr 2026, 9:00 amClosed
Sr. Store Officer (H) on behalf of Director AIIMS
1st floor, Main Hospital Store, AIIMS New Delhi
Procurement of Inj. Glofitamab
2026_AIMSD_903554_1
44/H/Inj. Glofitamab/2025-26
Open Tender
Drugs and Pharmaceutical Products
Buy
45 days
1st floor, Main Hospital Store, AIIMS New Delhi
Please refer Tender documents.
2 documents required · 2 mandatory
₹0
₹50,000
29 Apr 2026
24 Mar 2026
7 Apr 2026
24 Mar 2026
6 Apr 2026
24 Mar 2026
| Sl No | Description | Qty | Unit | Est. Rate | Est. Amount |
|---|---|---|---|---|---|
| 1RARE DISEASE MEDICINE | |||||
| 1.01 | Inj. Glofitamab 2.5mg | - | per vial | - | - |
| 2.01 | Inj. Glofitamab 10mg | - | per vial | - | - |
stage.html
html • 0.03 MB
tech_eval.pdf
boq_comp_chart.xlsx
xlsx
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
details.html
html • 0.03 MB
Tendernotice_1.pdf
PDF • 0.51 MB
TED44.pdf
Tender Documents • 0.63 MB
BOQ_949733.xls
BOQ • 0.33 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .